Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902950 · ClinicalTrials.gov registry record · Phase 4
TXA in the Reduction of Post-Op Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty
A Phase 4 study, sponsored by The Reading Hospital and Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT04902950 is a Phase 4 study that was terminated before completion, run by The Reading Hospital and Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT04902950, a Phase 4 study, was terminated before completion, sponsored by The Reading Hospital and Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to study the use of a drug, tranexamic acid (TXA) to decrease bleeding and fluid collections in patients undergoing excision of excess lower abdominal skin and soft tissue, otherwise known as a panniculectomy. The use of TXA in this study is experimental. TXA is a medication currently used in many surgical subspecialties to control bleeding. TXA is approved by the FDA as a medication taken by mouth for the treatment of heavy menstrual bleeding and as an injection in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. The use of TXA in this study is experimental, which means it is not approved by the FDA for topical use in decreasing bleeding during and after surgery. The results of this study will help the researchers determine if TXA is effective in decreasing blood loss following surgery. If effective, researchers hope this will result in earlier removal of post-operative drains leading to faster return to work or social activities
Interventions
- DRUG Saline
- DRUG Tranexamic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04902950
The ClinicalTrials.gov registry entry for NCT04902950 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Reading Hospital and Medical Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04902950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04902950 about?
NCT04902950 is a clinical study titled "TXA in the Reduction of Post-Op Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty". The purpose of this study is to study the use of a drug, tranexamic acid (TXA) to decrease bleeding and fluid collections in patients undergoing excision of excess lower abdominal skin and soft tissue, otherwise known as a panniculectomy. The use of TXA in this study is experimental. TXA is a medica...
What is the current status of trial NCT04902950?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2020-08-17. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT04902950?
The interventions under investigation include: Saline (DRUG), Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT04902950?
This trial is sponsored by The Reading Hospital and Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.